Impact of etravirine on hospitalization rate between 2005 and 2011 among heavily treated HIV-1-infected individuals on failing regimens

BACKGROUND: Etravirine (ETR), a non-nucleoside reverse transcriptase inhibitor (NNRTI) available in France since 2006, is indicated for antiretroviral-experienced HIV-infected adults, in combination with a ritonavir-boosted protease inhibitor (PI). To assess its clinical impact in routine care, we c...

Descripción completa

Detalles Bibliográficos
Autores principales: Potard, Valérie, Goujard, Cécile, Valantin, Marc Antoine, Lacombe, Jean Marc, Lahoulou, Rima, Chéret, Arnaud, Girard, Pierre Marie, Costagliola, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042265/
https://www.ncbi.nlm.nih.gov/pubmed/29996784
http://dx.doi.org/10.1186/s12879-018-3231-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042265/
https://www.ncbi.nlm.nih.gov/pubmed/29996784
http://dx.doi.org/10.1186/s12879-018-3231-5

Ejemplares similares